The fresh capital will be deployed towards scaling international operations, expanding the product portfolio and strengthening organisational capabilities
PlasmaGen Biosciences, a leading biopharmaceutical company focussed on blood plasma-derived therapeutics, announced that it has raised Rs 150 crores in a minority equity financing round at an Rs 1500+ crore valuation. The round was led by ViNS Bioproducts, a specialty biopharma company, with participation from prominent HNI family offices, pharmaceutical entrepreneurs and existing investors.
The financing reflects strong investor conviction in PlasmaGen’s operating model, manufacturing infrastructure, and long-term potential as a differentiated plasma biopharmaceutical platform. Since commencing commercial operations at its state-of-the-art manufacturing facility in 2024 – India’s first such facility by a pure-play company and only the fifth plasma fractionation facility in the country – PlasmaGen has delivered rapid revenue growth and is now preparing to enter international markets.
Founded in 2010 and headquartered in Bengaluru, PlasmaGen has raised over Rs 600 crores in total funding to date. The fresh capital will be deployed towards scaling international operations, expanding the product portfolio and strengthening organisational capabilities.
Vivek V Kamath, CEO, PlasmaGen Biosciences said, “The past year has been transformational for PlasmaGen, marking a step change in the scale and reach of the company. This momentum has put us on an exponential growth trajectory. With a clear plan and the support of this financing, we are well positioned to turn our ambition into enduring impact for patients and partners worldwide.”
Vinod Nahar, Founder and Executive Chairman, PlasmaGen Biosciences commented, “The support from our incoming and existing investors underscores their trust in PlasmaGen’s mission and capabilities. From the outset, our objective has been to create a world-class, India-based plasma biopharmaceutical platform that delivers consistent quality and meaningful patient impact. This investment further strengthens PlasmaGen’s position as a long-term partner to healthcare systems and patients, both in India and internationally.”
